How MSI and TMB Factor into Current Biomarker Testing Panels

Sanjiv S. Agarwala, MD

Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”

Related Videos

September 20, 2013

Realizing the Value in Personalized Medicine

Jennifer Malin discusses the aspects of value and how they are realized in personalized medicine

January 20, 2016

Which Stem Cell Properties Drive Which Cancers?

Dr Wainberg and Dr Gerson review the characteristics of these stem cells, what some of the medicines are doing right now, and some of the expectations in future clinical trials.